Background. It is important to identify vaccine-induced immune responses that predict the preventative efficacy of a human immunodeficiency virus (HIV)-1 vaccine. We assessed T-cell response markers as correlates of risk in the HIV Vaccine Trials Network (HVTN) 505 HIV-1 vaccine efficacy trial.
A vaccine effective at preventing HIV-1 acquisition would be a cost-effective and durable approach to halting the worldwide epidemic. However, despite decades of scientific research, only 4 candidates have advanced to efficacy trials; furthermore, most have been ineffective [1] [2] [3] [4] [5] [6] . The one exception is the replication-defective canarypox vaccine (ALVAC) plus recombinant gp120 protein (AIDSVAX) vaccine, which reduced the rate of HIV-1 acquisition by an estimated 31.2% in the RV144 trial (95% confidence interval [CI]: 1.1% to 52.1%; P = .04) [5] .
Identifying vaccine-induced immune-response biomarkers that predict a vaccine's ability to protect individuals from HIV-1 infection is a high priority [7] [8] [9] . Such biomarkers could expedite the development of an efficacious vaccine by providing a basis for rapidly advancing or discarding candidate vaccines, given immunogenicity data from early-phase studies.
A vaccine efficacy trial is the ideal setting for evaluating potential biomarkers as predictors of vaccine efficacy (ie, as correlates of protection) [10] [11] [12] . The first step is evaluating biomarkers as predictors of HIV-1 infection (ie, as correlates of risk). If a biomarker correlates with risk, additional data must be collected to evaluate whether it is also a correlate of protection [11] [12] [13] . Correlates of risk analyses have been performed in previous HIV-1 vaccine efficacy trials. In particular, the RV144 trial generated the hypotheses that the ALVAC plus AIDSVAX vaccine's efficacy was predicted by: (1) the binding of immunoglobulin G (IgG) antibodies to variable loops 1 and 2 in gp120; (2) to envelope (Env); and, in secondary analyses, (3) the combinatorial polyfunctionality analysis of antigen-specific T-cell subsets (COMPASS) Env CD4 + T-cell polyfunctionality score [14, 15] .
We assessed T-cell immune responses as potential correlates of risk in the HIV Vaccine Trials Network (HVTN) 505 HIV vaccine efficacy trial, which tested the multiclade DNA prime, recombinant adenovirus serotype 5 vector boost (DNA/rAd5) vaccine in circumcised, Ad5-seronegative U.S. men and transgender women who have sex with men. The study was halted on 22 April 2013 due to absence of vaccine efficacy. There was no significant effect of the vaccine on the primary infection endpoint of HIV-1 infection between week 28 and month 24 (hazard ratio [HR] = 1.25, 95% confidence interval [CI]: 0.29-2.21; P = .44), or on HIV-1 infection over the entire study period (HR = 1.29, 95% CI: 0.81-2.06; P = .28) [6] , even though the vaccine was immunogenic: among 40 vaccine recipients who remained HIV-1 uninfected, 100% generated IgG-binding antibodies to the vaccine strain envelopes, and 62% and 64% generated HIV-specific CD4 + and CD8 + T-cell responses, respectively [6] . Studying immune response biomarkers as correlates of risk in a vaccine trial with no vaccine efficacy enables the discovery of potential biomarkers that identify subgroups with positive vaccine efficacy and subgroups with negative vaccine efficacy. Alternatively, biomarkers correlating with risk might be markers of HIV-1 exposure or natural susceptibility to infection.
METHODS

Study Participants
HVTN 505 (ClinicalTrials.gov Identifier: NCT00865566) enrolled 2504 Ad5-seronegative and fully circumcised U.S. men or transgender women who have sex with men. Informed consent was obtained from all participants and all relevant guidelines of the authors' institutions were followed throughout the study. Participants were randomized to receive the DNA/rAd5 vaccine with HIV-1 gene inserts (gag, pol, multiclade Env [DNA and rAd5]) and nef (DNA only) or placebo (saline/vector-free diluent) (Figure 1 ) at weeks 0, 4, 8, and 24; further details are given in the Supplementary Material.
We assessed immune responses among vaccine recipients at week 26 (2 weeks post-final vaccination) as predictors of HIV-1 infection from week 26 through month 24, based on follow-up data collected prior to study unblinding on 22 April 2013. Using a nested case-control design described in detail in the Supplementary Material, we measured immune responses for 25 HIV-1-infected vaccine recipient "cases" and 125 HIV-1-uninfected vaccine "controls, " as well as in 19 placebo cases and 20 placebo controls to generate a reference distribution (Figure 1 ).
Laboratory Methods
A 12-color intracellular cytokine staining (ICS) assay was performed as described [16] with modifications. Briefly, previously cryopreserved peripheral blood mononuclear cells were stimulated with synthetic HIV-1 peptide pools, stained with fluorescent-labeled antibody conjugates, and analyzed by flow cytometry. Further details are provided in the Supplemental Material. The first primary immune response variable was the total magnitude of the CD4 + T-cell response, calculated as the net percent of CD4 + T cells expressing at least one of: CD154, interferon-γ (IFNγ), interleukin 2 (IL2), or tumor necrosis factor-α (TNFα), summed across the 4 HIV-1 proteins in the vaccine insert. The second primary immune response variable was the COMPASS Env-specific CD4 + T-cell polyfunctionality score [15] , defined as the proportion of antigen-specific cell subsets detected, weighted by their degree of functionality. Secondary immune response variables were the total CD8 + T-cell response magnitude, the Env-specific CD8 + T-cell polyfunctionality score, and the CD4 + and CD8 + T-cell log 10 -transformed total magnitude variables. Exploratory T-cell magnitude variables included the net percent of cells expressing IFNγ and/or IL2, the net percent of cells expressing IL2 and/or TNFα, the net percent of cells expressing each of the individual markers, and the T-cell immune response magnitudes for individual HIV-1 proteins and subproteins. Exploratory T-cell polyfunctionality variables were polyfunctionality scores for Nef, Pol, and Gag; the COMPASS functionality score for each protein (a variation on the polyfunctionality score proposed in [15] ); and the percent and log 10 -percent of cells expressing at least 2 or at least 3 markers (among CD154, IFNγ, IL2, TNFα, IL4, and granzyme B). For additional details, see the Supplementary Material.
Statistical Methods
To evaluate the immune response variables among vaccine recipients as predictors of HIV-1 infection, Cox proportional hazard models were used that account for the case-control sampling design and adjust for the baseline covariates age, race, body mass index (BMI, kg/m 2 ), and behavioral risk [17] . Both quantitative and binary ("low, " below the vaccine-group median, vs "high, " above the median) immune response variables were evaluated. To account for multiple testing in assessing exploratory immune response variables, q values were calculated; q < .20 was considered statistically significant. No adjustment for multiplicity was performed for analyses of primary or secondary immune response variables. All P values and q values are 2-sided. Additional details are provided in the Supplementary Material.
Machine learning analyses were used to discover immune response variable combinations optimally predictive of HIV-1 infection among vaccine recipients. First, in unsupervised learning, principal components analysis (PCA) was used to discover unique immune response profiles among vaccine recipients. The first and second principal components were associated with HIV-1 infection using Cox proportional hazards regression models that account for the sampling design and adjust for baseline covariates. Second, in supervised learning, logistic regression models with lasso penalty [18] and weights to account for case-control sampling were used to identify the baseline covariates and immune response variables that best predict HIV-1 infection. Model-predictive performance was assessed by the area under the receiver operating characteristic curve (AUC) and by the model-predicted proportion of vaccine recipients estimated to have less than half the HIV-1 infection risk of the placebo group, estimated using cross-validation. See the Supplementary Material for details.
RESULTS
Characterization of CD4 + and CD8 + Immune Responses
The DNA/rAd5 vaccine induced positive CD4 + and CD8 + immune responses to at least 1 HIV-1 protein in 65% and 75% of HIV-1-uninfected vaccine recipient controls, respectively. COMPASS polyfunctionality analysis identified 26 combinations of the 6 functional markers considered with elevated Env-specific responses among CD4 + T cells, and 19 with elevated Env-specific responses among CD8 + T cells. Some combinations were common across participants (eg, for CD4 + cells, combinations including CD154; for CD8 + cells, combinations including IFN-γ), and others were rare (eg, for CD4 + cells, IL2 without CD154; for CD8 + cells, IL2 without IFN-γ) ( Figure 2 ).
The 2 primary immune response variables, total HIV-1-specific CD4 + T-cell magnitude (Env, Gag, Pol, and Nef combined) and Env-specific CD4 + T-cell polyfunctionality, were moderately correlated among vaccine recipients (Spearman rank correlation r = 0.52; Supplementary Figure 1) . The secondary variables, total CD8 + T-cell magnitude and the Env-specific T-cell CD8 + polyfunctionality score, were more highly correlated (r = 0.76). Some exploratory immune response variables were highly correlated, such as response magnitudes for Figure 1 . Selection of participants for the case-control study. Participants were eligible for case-control sampling if they were primary endpoint cases (HIV-1-uninfected after week 28); had week-26 samples available, and were RNA-negative at week 26; or if they completed the month-24 visit HIV-1-uninfected and before study unblinding (22 April 2013) , received all study injections within the allowable visit windows (per-protocol), had sufficient sample quantities available at all immunogenicity time points, and had BMI and race values in strata with 1 or more cases. All eligible HIV-1 cases were sampled. Controls were frequency-matched to cases on treatment group (vaccine vs placebo), BMI, and race/ethnicity (white, black, or Hispanic); 5 controls were sampled per case for the vaccine group and 1 control per case was sampled for the placebo group.Abbreviations: BMI, body mass index (kg/m 2 ); HIV-1, human immunodeficiency virus 1; RNA, ribonucleic acid. different marker combinations for the same HIV-1 protein, and COMPASS functionality and polyfunctionality scores ( Supplementary Figures 2-5 ).
Univariate Analyses of Primary and Secondary Immune Response
Variables
We first analyzed the primary immune response variables individually in Cox proportional hazard models fit using data from vaccine recipients (Table 1) , using both quantitative immune response variables and indicators of high-versus-low immune responses based on dichotomizing responses at the median. There was no significant association between Env CD4 + polyfunctionality and HIV-1 infection, regardless of whether the quantitative immune response variable (HR = 0.73; P = . 15) or the binary high-versus-low response indicator (HR = 0.63; P = .29) was used. Similarly, there was no significant association between the total CD4 + magnitude and HIV-1 infection (HR = 0.71; P = .19).
In the analyses of secondary variables (Table 1) , the log-transformed total CD4 + magnitude was significantly inversely correlated with HIV-1 infection (HR = 0.59; P = .02). Specifically, each SD increase in the immune response was associated with a 41% lower risk of HIV-1 infection. Much stronger inverse correlations were identified between CD8 + immune responses and HIV-1 infection. Each SD increase in total CD8 + magnitude was associated with an estimated 82% decrease in the risk of HIV-1 infection (95% CI: 5% -96%; P = .04). The log-transformed total CD8 + magnitude had an inverse correlation with HIV-1 infection of similar strength (HR = 0.55; P < .01). The binary indicator of a high total CD8 + magnitude was associated with an estimated 76% lower risk of HIV-1 infection (95% CI: 33%-92%; P = .01). The Env CD8 + polyfunctionality score was another strong inverse correlate: A 1-SD increase in the score was associated with an estimated 66% decrease in the risk of HIV-1 infection (95% CI: 41%-81%; P < .01); likewise, a high Env CD8 + polyfunctionality score was associated with an estimated 79% lower risk of HIV-1 infection (95% CI: 41%-93%; P < .01). Figure 3 shows the distribution of these immune responses by HIV-1 infection outcome. Figure 4 shows the cumulative incidence of HIV-1 infection in participants with low versus high levels of these immune responses, estimated using the Kaplan-Meier method. Similar associations were identified when low outlying total CD8 + magnitudes were omitted (Supplementary Tables 13  and 14) , logistic regression models were used (Supplementary  Tables 15 and 16 ), Cox models omitted baseline covariates (Supplementary Tables 1 and 2) , and positivity calls were used to generate binary immune responses (Supplementary Table  17 ). Using natural cubic splines to capture potential nonlinear associations of quantitative immune response variables also resulted in similar associations, except for total CD4 + and CD8 + magnitudes where spline models suggested plateauing risk at high immune response levels (Supplementary Tables 18 and 19 ; Supplementary Figures 6 and 7) .
Risk of HIV-1 Infection by Low/High Immune Response Compared to Placebo Group Risk
Using Cox regression models, we compared the estimated HIV-1 infection risk among vaccine recipients by binary immune response to the estimated HIV-1 infection risk among placebo recipients. Risk in the vaccine group was significantly higher than in the placebo group, given a low CD8 + immune response (HR = 2.14, P = .02 for total CD8 + magnitude; HR = 2.30, P = .01 for Env CD8 + polyfunctionality). Moreover, risk was lower in the vaccine group than in the placebo group, given a high CD8 + immune response, although this tendency was not statistically significant (HR = 0.51, P = .18 for total CD8 + magnitude; HR = 0.47, Figure 2 . Heatmap of Env-specific marker-specific T-cell response probabilities (CD4 + on top, CD8 + on bottom). The columns correspond to the different marker combinations with detectable Env-specific responses (26 subsets for CD4 + and 19 for CD8 + ). The marker combinations are shaded by the markers they express (white, "off"; shaded, "on"), and ordered by degree of functionality, from 1 function on the left to 5 functions on the right. The average posterior probability of expressing each marker combination is shown, for vaccine versus placebo and case versus control groups. Marker combinations with average posterior probabilities less than 0.005 have been removed from the heatmap. The average posterior probability is shaded from white (zero) to dark (1). P = .15 for Env CD8 + polyfunctionality; Supplementary Figure 8 ). In contrast, the level of vaccine-induced CD4 + immune response was not significantly associated with a different HIV-1 infection risk than in the placebo group (P > .22).
Multivariate Analyses of Primary and Secondary Immune Response
Variables
When the Env CD4 + and CD8 + polyfunctionality scores and total CD4 + and CD8 + magnitude variables were examined together in a Cox regression model (excluding baseline covariates to avoid overfitting), only Env CD8 + polyfunctionality was a significant predictor of HIV-1 infection (HR = 0.33 per SD; P < .01; Model 1, Table 1 ). Substituting log-transformed total CD4 + and CD8 + magnitude variables in the model led to the same conclusion (Model 2, Table 1 ). A multivariate model, including binary CD4 + and CD8 + immune response variables, indicated that both a high Env CD8 + polyfunctionality score (P = .06) and a high total CD8 + magnitude (P = .07) were borderline-significant predictors of reduced HIV-1 infection risk (Model 3, Table 1 ).
Univariate Analyses of Exploratory Immune Response Variables
Among the 787 exploratory immune response variables studied, 147 were nominally significant predictors of HIV-1 infection among vaccine recipients in univariate models (P < .05; Supplementary Tables 3 and 4). Table 2 shows the subset found to be associated with HIV-1 infection based on the q < .20 criterion (22 out of the 787 exploratory variables examined). These variables, all inversely correlated with HIV-1 infection, included: CD4 + T-cell log-percent of cells expressing at least 3 markers in response to Pol; CD4 + T-cell log-magnitude response to Gag and Gag B; total CD8 + T-cell log-percent response of cells expressing at least 3 markers; total CD8 + T-cell log-magnitude response (various marker combinations); and CD8 + T-cell log-magnitude response (various marker combinations) to Env and Env subproteins. Gag-specific CD4 + and CD8 + T-cell immune responses are shown in Supplementary Figure 9 .
T-cell response magnitude variables that ignored background (ie, unstimulated response magnitude) had similar or even stronger associations with HIV-1 infection compared to their background-subtracted counterparts (Supplementary Tables 20  and 21 ).
Machine Learning Analyses of Multivariate Immune Response Profiles
Machine learning analyses were used to discover combinations of T-cell immune response variables (primary, secondary, or exploratory) that best predict HIV-1 infection among vaccine Figures 10 and 11) . In both analyses, the first principal component (PC) was found to explain a modest portion of the total variation in the immune responses (34% for CD4 + ; 29% for CD8 + ). The first CD4 + PC, representing a combination of responses to all HIV-1 proteins expressed in the vaccine, was weakly correlated with HIV-1 infection (P = .02 for the first PC; P = .87 for the second PC; Supplementary Tables 6 and 9 ). The first CD8 + PC, which was dominated by responses to Env, was very strongly correlated with infection (P < .01 for the first PC; P = .77 for the second PC; Supplementary Tables 7 and 10 ). When PCA was applied to all quantitative immune response variables, both PCs were nominally predictive of HIV-1 infection (P < .01 for the first PC; P = .05 for the second PC; Supplementary Figure  12 and Supplementary Tables 5 and 8 ). However, we found that including the first and second PCs in the Cox regression models for HIV-1 infection resulted in models with similar or inferior predictive performance compared to the Cox model that included the best single immune response variable among primary and secondary variables-the Env CD8 + polyfunctionality score-and baseline covariates (Table 3 ). Building models for HIV-1 infection using logistic regression with lasso did not identify any combinations of immune response variables with better predictive performance ( Table  3 ). The best-performing multivariate model was built using quantitative CD8 + immune response variables (cross-validated AUC = 0.72 [95% CI: 0.53, 0.87]; model-predicted proportion of vaccinees at less than half the HIV-1 risk of the placebo group = 0.17 [95% CI: 0, 0.48]). For this model, the most important variables were the Env CD8 + TNF log-magnitude (selected in 844 of 1000 models; Supplementary Table 11 ) and the Env CD8 + IL2 log-magnitude (selected in 819/1000 models); all other variables were selected in fewer than half the models. Including CD4 + immune response variables yielded models with poorer predictive performance. Supplementary  Table 12 contains results from models built using other supervised learning methods and that considered other subsets of immune response variables; none of these models demonstrated superior predictive performance. a Estimates of predictive performance for models of HIV-1 infection, considering different sets of immune response variables and using either PCA or logistic regression with lasso to combine the immune response variables with the baseline covariates, are shown. Model performance was measured by the ROC AUC and by the proportion of vaccine recipients that the model predicted to be at less than half the placebo group HIV-1 infection risk (Prop. low risk). A better model has a higher AUC and a higher Prop. low risk. Performance of the model that includes the best single immune response variable among primary and secondary variables-the Env-specific CD8 + polyfunctionality score-and baseline covariates is shown for comparison.
b Predictive performance measures were estimated using 1000 repeats of HIV-1 outcome-stratified 2-fold cross-validation. Abbreviations: CI, confidence interval; HR, hazard ratio; IFNγ, interferon-γ; IL2, interleukin 2; TNFα, tumor necrosis factor-α. 
DISCUSSION
This study identified unexpectedly strong inverse correlations between DNA/rAd5 vaccine-induced CD8 + T-cell immune responses recognizing epitopes in the vaccine-matched Env protein-in terms of both response magnitude and polyfunctionality-and HIV-1 infection. Compared to placebo recipients, vaccine recipients with high Env CD8 + polyfunctionality scores and with high total CD8 + response magnitudes were at decreased risk of HIV-1 infection (HR = 0.47, P = .15 for polyfunctionality; HR = 0.51, P = .18 for magnitude), whereas those with low Env CD8 + polyfunctionality scores and low total CD8 + response magnitudes were at increased risk (HR = 2.30, P = .01 for polyfunctionality; HR = 2.14, P = .02 for magnitude). Weaker inverse correlations were identified between the magnitudes of CD4 + responses recognizing Gag and Pol (measured on the log scale) and HIV-1 infection. Multivariate and machine learning analyses revealed that Env-specific log-transformed CD8 + magnitude variables were the dominant predictors of HIV infection. One possible explanation is that the Env CD8 + immune response variables are predictors of vaccine efficacy (ie, vaccine efficacy is negative among participants with low immune responses and positive among participants with high immune responses). In our view, the only plausible mechanism for vaccine enhancement among subjects with low Env CD8 + responses is if the vaccine expanded a population of highly susceptible Ad5-specific CD4 + T cells [19] ; placebo recipients received only saline/vector-free diluent and would therefore not have had this response. Our previous studies demonstrated that hexon epitopes recognized by adenovirus-specific T cells are commonly conserved across various adenovirus serotypes causing infection, and that preexisting memory Ad-specific CD4 + T cells may be boosted with the Ad5 vector [20] .
Conversely, it is possible that an unmeasured factor, possibly related to host genetics or innate immunity, is causing the inverse correlation we observed among vaccine recipients. Specifically, the Env-specific CD8 + responses may be markers of a natural resistance to HIV-1 infection.
Importantly, however, the observed data alone cannot confirm or refute these hypotheses. Additional data are needed to infer what the immune responses among placebo recipients would have been if they had been given the vaccine [11] [12] [13] , as discussed in [21] .
Another possibility is that the Env CD8 + immune responses are markers of HIV-1 exposure. We consider this unlikely; we made every attempt to eliminate this possibility by adjusting for the baseline behavioral risk score in our regression models.
We observed a trend toward positive vaccine efficacy during early follow-up that waned to zero over time (Supplementary Figure 13) . Therefore, another possibility is that the Envspecific CD8 + T-cell responses are predictors of positive early vaccine efficacy that subsequently wanes to zero. However, we were unable to probe this hypothesis by estimating vaccine efficacy over time by Env-specific CD8 + T-cell response, given the paucity of data.
Several lines of existing evidence relate to these possibilities. If Env CD8 + responses are bona fide predictors of vaccine efficacy, we would expect this effect to have been observed in nonhuman primate challenge studies, which afford a unique opportunity to assess immune correlates of vaccine efficacy [22] [23] [24] . To our knowledge, of the 14 nonhuman primate low-dose mucosal R5 simian immunodeficiency virus-HIV chimera or pathogenic simian immunodeficiency virus challenge studies published [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] , all but 1 [25] employing vaccines other than the DNA/ rAd5 regimen, only 2 identified vaccine-induced CD8 + T-cell responses as correlates of vaccine efficacy against infection, 1 using a live-attenuated simian immunodeficiency virus vaccine [28] and 1 using a rhesus cytomegalovirus vector vaccine; another found nonsignificant trends with an Ad26/Env vaccine [37] .
If Env CD8 + responses are markers of resistance to HIV-1 infection, we would expect that they would inversely correlate with HIV-1 infection across vaccine trials. However, the immune response variables we studied have not been evaluated as correlates in prior efficacy trials due to differences in vaccines and in immune response assays. In the HVTN 502 (Step) trial of the Merck Adenovirus 5 (MRKAd5) HIV-1 subtype B Gag/Pol/Nef vaccine-which did not include Env-only IFNγ, IL2, and TNFα T-cell immune responses to vaccine-matched proteins were measured by ICS; polyfunctionality was not formally assessed as a potential correlate [39] . The IFNγ/IL2 CD8 + Pol and CD4 + Gag T-cell response magnitudes were found to inversely correlate with HIV-1 infection using novel, more efficient statistical methods [40] . In the RV144 trial, the ALVAC/gp120 vaccine only generated CD4 + immune responses to the vaccine-matched Env [5, 14] . Although Env-specific CD4 + T-cell magnitude was not a significant correlate [14] , COMPASS Env-specific CD4 + T-cell polyfunctionality did inversely correlate with HIV-1 infection [15] . Last, in the Vax004 trial of the recombinant gp120 AIDSVAX vaccine, HIV-specific CD8 + T-cell proliferation was found to correlate directly with HIV-1 infection [41] .
Further research is needed to determine if the Env-specific CD8 + T-cell immune response variables we found to inversely correlate with HIV-1 infection in HVTN 505 are markers of natural resistance to HIV-1 infection in these and other at-risk groups.
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